This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Retina Associates of Cleveland, Inc.
Recruitment status was:  Active, not recruiting
Genentech, Inc.
Information provided by:
Retina Associates of Cleveland, Inc Identifier:
First received: November 9, 2009
Last updated: March 16, 2011
Last verified: March 2011
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Condition Intervention Phase
Venous Retinal Branch Occlusion Central Retinal Vein Occlusion Retinal Vein Occlusion Depression Drug: ranibizumab (Lucentis) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion

Resource links provided by NLM:

Further study details as provided by Retina Associates of Cleveland, Inc:

Primary Outcome Measures:
  • The primary outcome measures are changes in the VFQ-25, GHQ-12, and PHQ-9 survey scores from baseline through 24 weeks. [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Secondary outcome measures are change in macular edema measured by OCT and estimated by central retinal thickening and correlations between change in visual acuity, depression, and retinal findings such as neovascularization, rubeosis, and perfusion. [ Time Frame: 24 weeks ]

Estimated Enrollment: 45
Study Start Date: November 2009
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ranibizumab (Lucentis)
    0.5 mg, administered intravitreally every 4 weeks
    Other Name: Lucentis

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage into all four quadrants with dilated veins, or branch retinal vein occlusion, as documented on clinical exam
  • Age 18 years or over
  • Central macular edema on clinical exam as well as imaging with a central thickness of ≥ 250 microns
  • Visual acuity ranging from 20/8000 to 20/40
  • Media clarity and patient cooperation sufficient to allow adequate testing utilizing OCT and FA
  • No previous treatment that might compromise or confound assessment of the study outcomes
  • Ability to speak and read English

Exclusion Criteria:

  • Acute illness or cognitive or other impairment that, in the opinion of the investigator, would interfere with study requirements
  • Concurrent ocular conditions likely to significantly compromise vision and contribute the macular compromise
  • History of grid/focal laser in the study eye
  • History of vitreal surgery
  • Previous treatment with triamcinolone acetonide in either eye
  • Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
  • History of cerebrovascular accident within 1 year prior to Day 0
  • Inability to comply with study or follow-up procedures
  • Any cognitive defect as a result of mental disease, previous injury, or disease process that may interfere with interpretation of study results
  • Visual acuity better than 20/40
  • Pregnancy (positive pregnancy test) or lactation
  • Inadequate contraception in premenopausal women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01011374

United States, Ohio
Retina Associates of Cleveland
Cleveland, Ohio, United States, 44122
Sponsors and Collaborators
Retina Associates of Cleveland, Inc
Genentech, Inc.
Principal Investigator: Lawrence J Singerman, MD Retina Associates of Cleveland
  More Information

Responsible Party: Lawrence J. Singerman, MD, Retina Associates of Cleveland Identifier: NCT01011374     History of Changes
Other Study ID Numbers: FVF4638s
Study First Received: November 9, 2009
Last Updated: March 16, 2011

Keywords provided by Retina Associates of Cleveland, Inc:
Retinal vein occlusion

Additional relevant MeSH terms:
Retinal Vein Occlusion
Behavioral Symptoms
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on August 16, 2017